NasdaqGS:CNTABiotechs
Centessa Pharmaceuticals (CNTA) Is Up 9.6% After Positive ORX750 Phase 2a Narcolepsy Data - What's Changed
In recent days, Centessa Pharmaceuticals reported positive Phase 2a progress for its lead orexin receptor agonist ORX750 in narcolepsy and idiopathic hypersomnia, alongside updates on its broader neurology and neuropsychiatry pipeline.
This progress, combined with broad analyst support despite the absence of approved products, is sharpening attention on Centessa’s orexin-focused early-stage portfolio and upcoming clinical and regulatory milestones.
We’ll now examine how the encouraging...